Agave Health announces the deployment of the Unified Protocol across its clinical care model, strengthening its structured approach to treating adult ADHD. Deploying the Unified Protocol allows Agave ...
GlobalData on MSN
Otsuka’s ADHD drug reduces symptoms in Phase IIIb trial
Otsuka’s ADHD drug centanafadine is currently under review by the US FDA, with a PDUFA date of 24 July 2026.
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced ...
Viloxazine extended-release shows promise for treating adults with ADHD who also experience symptoms of depression and anxiety.
An ADHD rating scale is a tool used for reporting attention-deficit/hyperactivity disorder (ADHD) symptoms during the diagnostic process. There are numerous scales ...
Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition that affects around 2.5% of adults and 7% of children. It causes difficulties with attention, impulsivity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results